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ABO, H, secretor and Lewis histo-blood system genes control the expression of part of
the carbohydrate repertoire present in areas of the body occupied by microorganisms.
These carbohydrates, besides having great structural diversity, act as potential receptors
for  pathogenic and non-pathogenic microorganisms inﬂuencing susceptibility and resis-
tance to infection and illness. Despite the knowledge of some structural variability of these
carbohydrate antigens and their polymorphic levels of expression in tissue and exocrine
secretions, little is known about their biological importance and potential applications in
medicine. This review highlights the structural diversity, the biological importance and
potential applications of ABO, H, Lewis and secretor histo-blood carbohydrates.arbohydrate antigen
lycosyltransferases
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tant role in the symbiosis, commensalism and parasitism
continuum.2,5ntroduction
he relationships between humans and microorganisms that
olonize their body surface, cavities and mucous membranes
egin at birth and continue throughout life. These relation-
hips include a continuum of mutually beneﬁcial conditions
r otherwise (symbiosis, commensalism) as well as injury to
ne of the parties (parasitism).1 Some of the carbohydrates
xpressed by the epithelial cells of the body surface as well
s in the gastrointestinal, respiratory and genitourinary sys-
ems are closely involved in these relationships and play a
ritical role in the symbiosis, commensalism and parasitism
ontinuum.2,3
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ABO (ABO, 9q34.1), H (FUT1, 19q13.3), secretor (FUT2,
19q.13.3) and Lewis (FUT3: 19p13.3) histo-blood system genes
control the expression of part of the carbohydrate reper-
toire present in areas occupied by microorganisms.2,4 These
carbohydrates besides having great structural diversity, act
as potential receptors for pathogenic and non-pathogenic
microorganisms inﬂuencing susceptibility and resistance to
infection and illness. It is believed that this structural diversity
results from environment pressure and plays an impor-to de Biologia Molecular, Avenida Brigadeiro Faria Lima, 5416, São
Evidence supports the proposition that ABO, H, Lewis
and secretor histo-blood group carbohydrates are related
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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to susceptibility and resistance to infections and infectious
diseases.5–9 Experimental analyzes have clariﬁed the bio-
chemical and molecular basis underlying some of these
relationships.10–12 This review highlights the structural diver-
sity and biological importance of ABO, H, Lewis and secretor
histo-blood carbohydrates.
Histo-blood  group  systems
The expression “histo-blood system” was ﬁrst proposed for
the ABO system.13 Later, it was extended to H, Lewis and
secretor systems as their carbohydrates are also expressed
in other tissues and exocrine secretions.14 These histo-blood
group systems have strong relationships at genomic, enzy-
matic, biochemical, tissue and immune levels. Knowing the
structural variability of their carbohydrate antigens allows us
to understand the evolutionary importance and biological role
especially in terms of diseases.2
The International Society for Blood Transfusion (ISBT)
Working Party on Red Cell Immunogenetics and Blood Group
Terminology identiﬁes each blood group system according to
its discovery (http://www.isbtweb.org/working-parties/red-
cell-immunogenetics-and-blood-group-terminology/). ABO,
Lewis and H histo-blood group systems are identiﬁed by the
numbers 001, 007 and 018, respectively. As secretor is not a
true blood group system, it was not included among those
recognized by the ISBT Working Party. However, as it controls
the expression of ABO and Lewis carbohydrates in tissues
and exocrine secretions it must be considered an alloantigen
system.15
Phenotyping  of  histo-blood  group  systems
Histo-blood group systems are commonly identiﬁed by or
inferred from red blood cell phenotyping. Different phe-
notypes are known including ABO [A, B, AB, O], H [H,
H-deﬁcient], secretor [secretor, non-secretor] and Lewis
[Le(a+b−), Le(a−b+), Le(a+b+), Le(a−b−)].16 The ABO system
is characterized by the presence or absence of two carbo-
hydrate antigens (A and B) on the red blood cell membrane
and three regular antibodies (Anti-A, anti-B, anti-A,B) in the
blood plasma.15 The H system is characterized by the pres-
ence of only one carbohydrate antigen (H) on the red blood
cell membrane. H-deﬁcient individuals contain one regular
antibody (anti-H) in the blood plasma. Three rare types of
H-deﬁcient phenotypes have been described: the classical
Bombay phenotype which is non-secretor, the H-partially deﬁ-
cient phenotype which is non-secretor and the Para-Bombay
phenotype which is secretor.15,16
Secretors express the ABO carbohydrates in exocrine secre-
tions in addition to in red blood cells. On the other hand,
non-secretors express ABO carbohydrates only in red blood
cells. Le(a+b−)  phenotype correlates to a non-secretor pheno-
type while Le(a−b+) correlates to a secretor phenotype and
Le(a+b+) correlates to a weak secretor phenotype. Le(a−b−)
can be secretor or non-secretor. However, due to potential
cross-reactivity between anti-Lea and anti-Leb antisera and
even the weak adsorption of Lea and Leb carbohydrates in the
red blood cell membrane, this correlation is not always true,
particularly in diseases.17,18 2 0 1 6;3  8(4):331–340
The identiﬁcation of red blood cell phenotypes is com-
monly based on an agglutination reaction with tests
performed with slides, tubes, microplates, gel column, and
automation.19 However, the results are affected by the method
used and the quality of antisera and can be inaccurate espe-
cially in relation to the Lewis histo-blood group system.15,17
Therefore, red cell serology techniques alone are not sufﬁ-
cient to characterize the structural diversity of histo-blood
group carbohydrates in tissues and exocrine secretions. As
the genes of these histo-blood group systems all interact, the
combination of serology and genotyping is a good strategy to
predict the diversity of carbohydrates expressed in tissues and
exocrine secretions.17 Additionally, immunochemistry, proton
nuclear magnetic resonance (NMR) imaging and mass spec-
trometry (MALDI and Q-TofMS/MS) are useful tools to resolve
the carbohydrate structure and diversity; however, these tech-
niques and some of the reagents required are not routinely
available.2
Histo-blood  group  phenotype  frequencies  in  populations
Since the beginning of the last century, studies on population
variability demonstrated that the histo-blood group pheno-
types occur in all populations but their frequencies vary widely
from one ethnicity to another.20 The O phenotype is common
among Africans and South American natives while A and B
are common in North European and Asian countries, respec-
tively. H-deﬁcient phenotypes are rare in all populations but
they are more  frequent in India and Reunion Island, located
in the Indian Ocean. Although present in all populations, the
secretor phenotype occurs in 80% of Caucasians. The Le(a+b−)
phenotype is found in more  than 20% of Caucasians and Blacks
but it is rare in Asians. Le(a−b+) is frequent in all populations
but Le(a+b+) is more  common in Asians and Polynesians than
populations from the Western world. Le(a−b−) is rare in Cau-
casians but is common among Blacks.16,21 The reasons why
the differential distribution of histo-blood phenotypes occurs
at population level are not fully understood but it is believed
that selective pressure imposed by disease-causing microor-
ganisms contributed to this process.9
Biochemical  basis  of  histo-blood  group  carbohydrates
ABO, H, secretor and Lewis histo-blood group carbohy-
drates are not primary gene products. They are synthesized
by speciﬁc glycosyltransferases encoded by the ABO, FUT1,
FUT2 and FUT3 genes.15 These enzymes incorporate sequen-
tially, monosaccharide units to linear or branched precursor
oligosaccharide chains, modifying and creating new antigenic
speciﬁcities.16
The biosynthetic pathways and the biochemical basis of
these histo-blood group systems were established from glyco-
proteins in ovarian cyst ﬂuids. It was established that their
carbohydrate antigens are oligosaccharide chains present
as free forms or bound to sphingolipids (glycolipids) or
proteins (glycoproteins). Pioneer studies revealed that the
glycosyltransferases have functional similarities and require
precursor oligosaccharides, nucleotide sugar donors and diva-
lent ions.22,23
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Table 1 – Linear structure of precursor oligosaccharide
chains of the ABO, H, Lewis and secretor histo-blood
group systems.
Types Terminal structures Expressed forms
1 Gal1→3GlcNAc1-R Glycoproteins, glycolipids
2 Gal1→4GlcNAc1-R Glycoproteins, glycolipids
3 Gal1→3GalNAc1-R Glycolipids
4 Gal1→3GalNAc1-R Glycolipids
5 Gal1→3Gal1-R Synthetic structure
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Source: Adapted from Oriol.16
arbohydrate  units  and  precursor  oligosaccharide  chains
ix types of monosaccharides are found in the ABO, H, Lewis
nd secretor histo-blood group carbohydrates: -d-glucose
Glc), -d-N-acetylglucosamine (GlcNAc), -d-galactose (Gal),
-d-N-acetylgalactosamine (GalNAc), -fucose (Fuc) and d-
annose (Man). Another monosaccharide carrying nine
arbon atoms, -d-N-acetylneuraminic acid (NeuAc) may also
e found in these carbohydrates. l-Fucose is the immunodom-
nant monosaccharide present in H, Lea and Leb carbohydrates
hile N-acetylgalactosamine (GalNAc) and galactose (Gal) are
he immunodominant monosaccharides present in A and
Leb, and B and BLeb carbohydrates, respectively.23
Six types of precursor oligosaccharide chains have been
haracterized. Type 1 is found in the epithelium of the gas-
rointestinal, respiratory, genitourinary tracts and in exocrine
ecretions. Type 2 is predominant in hematopoietic tissue and
ascular endothelium. Type 3 can be found linked to mucins
r as an extension of the A Type 2 carbohydrate due to the
ddition of a Galactose to the terminal N-acetylgalactosamine.
ype 4 is abundant in renal tissue. Type 5 is synthetic and
as not yet been isolated from human tissues. Type 6 is
ound in human intestinal cells. The glycosylation of any of
hese precursor oligosaccharide chains give rise to different
arbohydrate antigens, which may differ in the spatial con-
ormation and afﬁnity to monoclonal antibodies.13,16,18,23,24
able 1 shows the linear structures of the six precursor
ligosaccharide chains.The structural diversity of the ABO, H, Lewis and secretor
isto-blood group carbohydrates is enormous and inﬂu-
nced by a range of factors. The type of monosaccharide
nd the glycosidic bond between them, the ionic charge,
Table 2 – ABO, H, Lewis and secretor histo-blood group systems
carbohydrate structures of type 1 and type 2 precursor oligosac
Systems Genea Chromosome
location
Enzyme 
H FUT1 19q13.3 1,2-Fucosyltransferase 
Secretor FUT2 19q13.3 1,2-Fucosyltransferase 
Lewis FUT3 19p13.3 1,3/4-Fucosyltransferase 
ABO ABO 9q.34.1 1,3-N-Acetylgalactosaminiltransfe
1,3-D-Galactosyltransferase 
Source: Adapted from Schenkel-Brunner.23
EC: Enzyme Commission Number; GDP: guanidine diphosphate; UDP: urid
a As stated by Human Genome Committee. 1 6;3  8(4):331–340 333
the carbon ring size, the linearity and branching, the chain
extension, and  and  anomeric conformations, result
in more  than 1.05×1012 possible structural combinations
that can be obtained from the combinations of these six
monosaccharides.25 Additionally, the structural differences in
these precursor oligosaccharides favor structural variability
and raise the complexity of the carbohydrate repertoire in
tissues and exocrine secretions.2
Histo-blood  group  glycosyltransferases
The glycosyltransferases acting on the biosynthesis of ABO, H,
secretor and Lewis histo-blood group carbohydrates are struc-
turally related to type II transmembrane glycosyltransferases
and have some common characteristics.23 They require uri-
dine diphosphate (UDP) and guanidine diphosphate (GDP) as
nucleotide sugar donors as well as divalent ions to sequen-
tially incorporate monosaccharide units into the precursor
oligosaccharide chains.26 To modify and create new ABO, H,
Lewis and secretor histo-blood group carbohydrate structures,
some of these enzymes compete for the same precursor.
Therefore the presence, absence or combination of these gly-
cosyltransferases will determine the quality and the quantity
of carbohydrates expressed by individuals.2,15 Table 2 presents
general characteristics of the histo-blood group glycosyltrans-
ferases and the carbohydrate antigens synthesized.
Some glycosyltransferases acting on the histo-blood group
carbohydrate biosynthesis have redundancy and degenera-
tion. Redundancy is observed when two separate enzymes
synthesize the same antigen. For example, FUT1 gene-deﬁned
fucosyltransferase and FUT2 gene-deﬁned fucosyltransferase
are capable of synthesizing the H Type 2 carbohydrate from the
same precursor oligosaccharide (Type 2). Degeneration occurs
when the same enzyme synthesizes different carbohydrate
structures. For example, FUT2 gene-deﬁned fucosyltransferase
is capable of synthesizing H Type 1 and H Type 2 carbohydrates
from their respective Type 1 and Type 2 precursor oligosaccha-
rides. The rare phenotypes B(A) and A(B) which illustrate the
synthesis of small amounts of A carbohydrate by the group B
galactosyltransferase (GTB) and vice versa is another exam-
ple of degeneration in the ABO histo-blood group system.
Additionally, FUT3 gene-deﬁned fucosyltransferase is capable
of synthesizing at least four different histo-blood group car-
bohydrates (Lea, Leb, ALea and ALeb) derived from the type
, gene location, glycosyltransferases and synthesized
charides.
Abbreviation ECb Nucleotide
donor
Synthesized
carbohydrate
FUTI 2.4.1.69 GDP H type 2
FUTII 2.4.1.69 GDP H type 1
FUTIII 2.4.1.65 GDP Lea, Leb,  ALeb, BLeb
rase GTA 2.4.1.40 UDP A type 1, A type 2
GTB 2.4.1.37 UDP B type 1, B type 2
ine diphosphate.
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1 precursor oligosaccharide.27 Redundancy and degeneration
create additional levels of complexity in these histo-blood
group systems.16 The level of expression as well as the loca-
tion of these enzymes in the Golgi compartments inﬂuence
their competition for monosaccharide donors and acceptors,
determining variations in the type, size and amount of each
synthesized carbohydrate structure.15
Biosynthesis  of  histo-blood  group  carbohydrates
The histo-blood group carbohydrates synthesized from type 2
precursor oligosaccharides are intrinsic to the red blood cell
membrane as they are expressed by red blood cell precur-
sor cells. However, those synthesized from type 1 precursor
oligosaccharide (A, B, H, Lea and Leb) are extrinsic since they
originate in the liver, pancreas, kidney and small intestine, are
transported from their place of synthesis to the blood plasma
and then adsorbed into the red blood cell membrane.27,28
The biosynthesis of ABO, H, Lewis and secretor histo-
blood carbohydrates is a complex event and dependent
on interactions between FUTI, FUTII, FUTIII, group A N-
acetylglucosaminyltransferase (GTA) and GTB proteins.27
FUTI, GTA and GTB allow the synthesis of H, A and B car-
bohydrates from type 2 oligosaccharides in mesodermal and
hematopoietic tissues and vascular endothelium.29 FUTII,
FUTIII, GTA and GTB allow the synthesis of H, A, B, Lea, Leb,
ALeb and BLeb carbohydrates from the type 1 oligosaccharides
in ectodermal tissues such as the gut, respiratory and urinary
mucosae and exocrine secretions.16 Therefore, these interac-
tions result in a different tissue proﬁle of carbohydrates to that
found on the red blood cell membrane.2,15
Additional complexities occur at a tissue level. For exam-
ple, the expression of ABO and Lewis carbohydrates on pyloric
and duodenal mucosae is related to the migration of cells
from Brunner glands.30 Cells migrating to the surface of the
gastric and duodenal epithelium express ABO and Lewis car-
bohydrates under the control of FUTII, FUTIII, GTA and GTB.
Those migrating to deep areas of the Brunner glands express
these carbohydrates under the control of FUTI, GTA and
GTB.16
The synthesis of ABO carbohydrates is similar in mesoder-
mal  tissues as in ectodermal tissues but under distinct genetic
control. FUTI acts like FUTII but it generally uses type 2 pre-
cursor oligosaccharides to form the H type 2 carbohydrates. H
type 2 carbohydrates can be converted into A type 2 and B type
2 carbohydrates by GTA and GTB, respectively.15,16 Despite the
reduced diversity, these type 2 carbohydrates are crucial in
transfusion procedures and solid organ transplantation.
In ectodermal tissues, FUTII transfers a Fuc unit through a
1→2 glycosidic bond to the carbon 2 of the terminal Gal of
the type 1 precursor oligosaccharide building up the H type 1
carbohydrate. This structure can be converted into A type 1 or
B type 1 by GTA or GTB, respectively. GTA adds a Gal-NAc unit
through a 1→3 glycosidic bond to carbon 3 of the terminal Gal
of the H type 1 carbohydrate. GTB adds a Gal monosaccharide
through a 1→3 glycosidic bond to carbon 3 of the terminal
Gal of the H type 1 carbohydrate.31
The synthesis of Lewis antigens occurs in different organs
increasing the complexity of histo-blood group systems. 2 0 1 6;3  8(4):331–340
FUTIII creates new antigenic speciﬁcity and diversiﬁes the pre-
vious carbohydrates by the synthesis of Lea, Leb, ALeb and
BLeb. It incorporates a Fuc molecule by a 1→4 glycosidic bond
to carbon 4 of the subterminal Glc-NAc of the type 1 precur-
sor oligosaccharide to form the Lea carbohydrate. By the same
reaction, FTUIII forms the Leb carbohydrate from the H type 1
antigen. FUTIII can add a second Fuc unit by a 1→4 glycosidic
bond to the carbon 4 of the N-acetylglucosamine subtermi-
nal antigens A and B, converting them into ALeb and BLeb
carbohydrates, respectively.16
The role of the functional FUTII is crucial to the action of
other histo-blood group glycosyltransferases in diversifying
the histo-blood group carbohydrates in secretors. It synthe-
sizes the H type 1 carbohydrate, the common substrate for
GTA, GTB and FUTIII. Thus, these enzymes compete for the
same substrate and their efﬁciency will determine the level of
expression of each carbohydrate structure. For example, due
to the absence of GTA and GTB, the O phenotype expresses a
high level of the Leb carbohydrate. On the other hand, the A, B
and AB phenotypes express more  ALeb and BLeb than Leb car-
bohydrates. Since non-secretors do not express an active FUTII
they will form the Lea carbohydrate from the type 1 precursor
oligosaccharide if they carry a functional FUTIII independent
of their ABO phenotype.15,16,21 For example, this set of gly-
cosylation processes seems to modulate innate immunity
responses in the mucosa and may contribute to the risk of gas-
tric disease by reducing the bacterial density and associated
inﬂammation in Helicobacter pylori infection.32
Alternative  nomenclature  for  histo-blood  group
carbohydrates
ABO, secretor and Lewis carbohydrates can be named by
the number of monosaccharide units present in their struc-
ture and by the type of precursor oligosaccharide. For
instance, A-4-6 refers to A carbohydrate antigen carrying
four monosaccharide units derived from the type 6 precursor
oligosaccharide while H-5-2 refers to H carbohydrate speci-
ﬁcity with ﬁve monosaccharide units derived from type 2
precursor oligosaccharide.31 All these carbohydrates react
with commercial polyclonal and monoclonal antibodies but
they present distinct spatial conformations which can be
recognized by some speciﬁc monoclonal antibodies as well
as microbial adhesins.18,33,34 Figure 1 illustrates the biosyn-
thesis of histo-blood group carbohydrates from the type 1
precursor oligosaccharide. Table 3 contains the combinations
of histo-blood group glycosyltransferases, the carbohydrates
expressed, and the mucosa and red blood cell phenotypes.
Carbohydrate  structural  variations  in  common  and  rare
histo-blood  groups
A and B carbohydrates present a simple structural difference
on carbon 2 of the terminal GalNAc and Gal, respectively.
GalNAc has an N-acetyl group linked to carbon 2 whereas
a hydroxyl group is linked to the same carbon in Gal. This
small difference changes the tridimensional conformation of
the terminal A and B carbohydrate portions even if other
parts remain unaltered. This distinct portion contains epi-
topes that selectively react with anti-A and anti-B antibodies.
rev bras hematol hemoter. 2 0 1 6;3  8(4):331–340 335
Galβ1→3GlcNAc-R
Galβ1→3GlcNAc-R
Galβ1→3GlcNAc-R
GalNAcα1→3Gal β1→3GlcNAc-R
GalNAcα1→3Gal β1→3GlcNAc-R
Galα1→3Gal β1→3GlcNAc-R
Galα1→3Gal β1→3GlcNAc-R
Galβ1→3GlcNAc-R
Fuc Fuc
α1→2
α1→2α1→2
α1→2 α1→4α1→2 α1→4
α1→2 α1→4
α1→4
FUTIII
FUTII
FUTIII
FUTIII FUTIII
H type 1
A type 1 B type 1Fuc
Fuc Fuc Fuc FucBLebALeb
Fuc
Fuc
GTA GTB
FucLea
Leb
Figure 1 – Biosynthesis of ABH-Lewis from type 1 precursor oligosaccharides. Guanidine diphosphate and uridine
d
S
A
t
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a
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p
p
s
Tiphosphate indicate the monosaccharide donors.
ource: Adapted from Oriol16 and Schenkel-Brunner.23
nti-A,B antibodies can react with the common portions of
hese carbohydrates.25
A1, A2 and some rare ABO subgroups also present struc-
ural differences in their carbohydrates as revealed by an
nalysis of glycolipids. Immunochemical studies by thin layer
hromatography and monoclonal antibodies demonstrated a
redominance of the A type 4 carbohydrate in the A1 com-
ared to the A2 subgroup.34 Additionally, novel carbohydrate
tructural variations were observed in weak A subgroups.33
hese studies suggest that mutations in the A gene allow the
Table 3 – Histo-blood group glycosyltransferases, carbohydrates
ABO FUTII FUTIII Carbohy
A, B, AB, O Active Active H, A and/or
Lea, Leb, AL
A, B, AB, O Active Inactive H, A and/or
A, B, AB, O Inactive Active Lea
A, B, AB, O Inactive Inactive POa
a Type 1 precursor oligosaccharyde.expression of variant GTA which seems to be potentially able
to synthesize a novel ABO carbohydrate structure.
Lea and Leb differ not only by the number of Fuc units, but
also by the length of the oligosaccharide chains. The Lea car-
bohydrate is monofucosylated and Leb is difucosylated. While
these chains are short in Leb they are elongated in most car-
bohydrates carrying Lea speciﬁcity.24,35 These differences are
coincident, respectively, with the presence and absence of
a functional FUT2 gene-deﬁned fucosyltransferase. The rea-
sons for these differences are not totally understood from the
 and mucosa and red blood cell phenotypes.
drates Mucosa phenotypes Red blood cell
phenotypes
 B
eb, BLeb
Secretor
Lewis positive
A,  B, AB, O
Le(a−b+)
 B Secretor
Lewis negative
A,  B, AB, O
Le(a−b−)
Non-secretor
Lewis positive
A,  B, AB, O
Le(a+b−)
Non-secretor
Lewis negative
A,  B, AB, O
Le(a−b−)
oter.336  rev bras hematol hem
evolutionary perspective but it is possible that they result from
biological pressure by microorganisms that colonize areas of
the body where these carbohydrates are expressed.2 Appar-
ently, the epitopes of Lea extended carbohydrates offer better
access to anti-Lea antibodies, reducing cross reactivity com-
pared to anti-Leb.18
Variability  and  biological  importance  of  histo-blood  group
carbohydrates
The environment exerts constant pressure on living beings
and drives them to create diversity in order to evolve and be
perpetuated in nature with the maintenance of diversity being
regulated by the selection of the best adaptation. Since diver-
sity results directly from genetic variations, microorganisms
and diseases are essential factors that act in the selection and
maintenance of species diversity.36–39
The activity of FUTI, FUTII, FUTIII, GTA and GTB in the
glycosylation of precursor oligosaccharides, besides creat-
ing new antigenic structures, diversiﬁes the pre-existent
structures allowing a high degree of variability.2 The variabil-
ity of histo-blood group carbohydrates extends beyond the
boundaries of gene and glycosyltransferase polymorphisms.40
Distinct levels of glycosylation in precursor oligosaccharides
are responsible for the carbohydrate structural diversity and
the polymorphisms seen in these antigenic systems. The ﬁrst
level, controlled by FUTIII, results in the synthesis of the Lea
carbohydrate. The second level, controlled by FUTI and FUTII,
results in the expression of H type 2 and H type 1 carbohy-
drates, respectively. At the third level, controlled by FUTIII, the
H type 1 antigen is converted into Leb. GTA and GTB act at the
fourth level allowing the synthesis of A type 1 and B type 1,
and A type 2 and B type 2 carbohydrates from H type 1 and
type 2 carbohydrates, respectively. Finally, the ﬁfth level, also
controlled by the FUTIII enzyme, results in the conversion of
A type 1 into ALeb and B type 1 into BLeb.16
FUTI, FUTII, FUTIII, GTA and GTB create -glycosidic
bonds to incorporate each monosaccharide unit in precursor
oligosaccharides. However, the inner core of these precur-
sors contains -glycosidic bonds.23 Maybe this feature stops
pathogenic microorganisms able to produce -glucosidase to
use histo-blood group carbohydrates as receptors by break-
ing glycoside bonds of -glycosylated oligosaccharide chains.
This suggests a potential reason for the abundance of -
carbohydrate structures in the gastrointestinal, respiratory,
and genitourinary tracts and exocrine secretions. These sites
are inhabited by great diversity of microorganisms and it is
possible that the -glycosidic bonds protect the inner core
of the precursor oligosaccharides from microbial exoglycosi-
dases attack.2
Currently, there is strong evidence that these histo-blood
group carbohydrates and the microbial adhesins that rec-
ognize them are important links in the relationship that
humans have with the microorganisms that colonize their
body surface, cavities and mucosa.5,8,41,42 The nature of the
interactions between parasites and their hosts is complex,
but it is also possible that the ABO, secretor and Lewis
histo-blood group carbohydrates represent important pieces
in this process. Maybe the histo-blood group glycosyltrans-
ferases have evolved to control the part of synthesis of 2 0 1 6;3  8(4):331–340
oligosaccharides expressed in the gastrointestinal, respiratory
and genitourinary tracts through glycosylation and struc-
tural diversiﬁcation. This strategy may represent an important
biological event in the change of potential receptors for
pathogenic microorganisms. Therefore, the contribution of
ABO, H, secretor and Lewis histo-blood group systems in
the diversity of populations may be associated with greater
chance of success of our species in epidemic events.2
In this scenario, ABO, H, secretor and Lewis histo-blood
group systems contribute with their different polymorphic
levels to the ethnic diversity of the human species acting
through mechanisms of evolution such as gene ﬂow, genetic
drift, founder effect, and natural selection.36,43 Through
glycosylation and structural diversiﬁcation of precursor
oligosaccharides, these systems inﬂuence the glycoconjugate
repertoire expressed in mucosae and exocrine secretions.40,42
Consequently, they affect the innate immune response, sus-
ceptibility to infections and the parasitism, symbiosis and
commensalism continuum.1,42,44
Medical  importance  of  histo-blood  group  carbohydrates
The carbohydrate variability resulting from these histo-blood
group systems has important implications in susceptibility
to infections, innate and adaptive immune responses, can-
cer, solid organ transplantation as well as new technologies
applied to blood transfusion. Due to the simplicity and low
cost of identifying histo-blood group phenotypes in red blood
cells, a large number of independent, quick, simple studies
explored them as potential markers for diseases. Many  of
them did not consider the diversity of carbohydrates in the
tissues infected by microorganisms as well as the strains or
serotypes of the same microorganism among other possible
confounding factors.44 However, some well-designed studies
provided a better understanding of the potential relationships
between histo-blood group carbohydrates and microorgan-
isms as well as their ethnic distribution worldwide.
Helicobacter pylori strains expressing the blood group bind-
ing adhesin (BAbA) are able to bind to the Leb carbohydrate
that is highly expressed in gastric epithelial cells related to O
and secretor histo-blood groups.45 Additionally, the observa-
tion that South American specialist strains of H. pylori are more
able to bind to H type 1 and Leb carbohydrates than generalist
strains that are able to bind to other histo-blood group carbo-
hydrates is coincident with the predominance of the O blood
group in Amerindians.46 These studies offered one explana-
tion for an old enigma: Why individuals with the O blood group
are more  prone to gastroduodenal diseases such as gastritis
and peptic ulcers.
It is believed that the low and high frequencies of O and
B blood groups, respectively, in some areas of Bangladesh
are related to selective pressure imposed by the severity of
cholera.47 The severity of this disease is related to the cholera
toxin secreted by Vibrio cholera that binds more  strongly
to the H type 1 carbohydrate than the B carbohydrate.48
Another suggestion is that the high frequency of the O blood
group in endemic areas of malaria results from selective
pressure related to the severity of this disease caused by
Plasmodium falciparum.49 These authors hypothesize that indi-
viduals carrying this phenotype have reduced cytoadherence
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Table 4 – Examples of associations between some histo-blood group phenotypes and microorganisms.
Microorganisms Histo-blood group phenotypes Biological effects
Gastrointestinal tract
Helicobacter pylori O, Le(a−b+) Peptic ulcers, Gastritis
Escherichia coli B Gastrointestinal infection
Giardia lamblia A Re-infestation
Toxoplasma gondii B Not determined
Candida albicans O, non-secretor Gastric inﬂammation
Vibrio cholera O, Le(a+b−) Severe diarrhea
Salmonella typhimurium B Typhoid fever
Norovirus Non-secretor Gastroenteritis
Respiratory tract
Streptococcus pneumoniae A  and O Pneumonia
Streptococcus pyogenes A, non-secretor Rheumatic fever
Inﬂuenza A O Inﬂuenza
Mycobacterium tuberculosis O  Tuberculosis
Genitourinary tract
Escherichia coli A, B, Le(a+b−) Urinary infection
Pseudomonas aeruginosa B Upper urinary infection
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Source: Adapted from Blackwell et al.44
f P. falciparum to red blood cells and consequently have
ome survival advantage compared to individuals with non-
 and non-Le(a−b−) phenotypes who tend to develop severe
alaria.
Cholera, malaria and H. pylori infection affect individuals
t any age. However, the ﬁrst two tend to be more  severe than
he gastric diseases caused by H. pylori. Therefore, it is possible
hat cholera and malaria exert greater selective pressure by
eath before reproductive age than H. pylori infection, thus
ontributing to the low and high frequencies of O blood group
ndividuals in endemic areas of these diseases.
There is convincing evidence that the H carbohydrate in
uman milk contributes to the protection of infants against
ampylobacter jejuni and other enteric pathogens. By bind-
ng to speciﬁc ligands, the H type 2 carbohydrate inhibits
he attachment of these microorganisms to intestinal cells
hereby protecting breastfeeding babies.50 Non-secretors are
elatively resistant to infection by norovirus and secretors
resent a variable degree of susceptibility since this virus uses
ome histo-blood group carbohydrates in the gastrointestinal
ract as receptors. About half of secretors are susceptible to
nfection, develop an early mucosal immune response with
peciﬁc IgA and become protected. The rest of these individu-
ls develop a late mucosal immune response with speciﬁc IgG
n IgA antibodies.51 Histological analysis of gastric mucosa
rom O, non-secretor histo-blood group patients infected by H.
ylori revealed a higher level of lymphocyte inﬁltration com-
ared to other phenotypes.52 Higher levels of interleukin-6
IL-6), tumor necrosis factor alpha (TNF-)  and nitric oxide
NO) are produced by monocytes of O blood group individu-
ls compared to non-O blood groups.53 Taking together these
ata demonstrate that the diversity of histo-blood group car-
ohydrates can modulate, at least in part, the innate and
daptive immune responses. Table 4 presents some examples
f associations between histo-blood group phenotypes and
icroorganisms.
Associations of histo-blood groups systems with cancer
ave been published in the past but many  of them found lowUrethral infection
relative risk. An old study carried out by Aird et al. with a large
sample size found that A blood group individuals have 20%
higher risk of developing stomach carcinoma than O blood
group subjects.54 More recently, two large, independent, and
prospective cohorts showed that people with A, B and AB blood
groups are more  likely to develop pancreatic cancer than those
with O blood groups.55
Some studies have reported loss and aberrant expressions
of histo-blood group carbohydrates at different stages of can-
cer. Loss of usual histo-blood group carbohydrates seems to
correlate with a poor prognosis. Lee et al. demonstrated that
the loss of the A carbohydrate in the tumor has a poor progno-
sis in non-small cell lung cancer.56 It has been demonstrated
that the expression of H type 1 carbohydrates in the normal
colon is under the control of FUT2 gene-encoded fucosyltrans-
ferase. However the aberrant expressions of H type 2 and H
type 3/4 carbohydrates in colon cancer tissues of secretors
is regulated by the same enzyme.57 The reasons underlying
these changes have not been clariﬁed. It has been pointed
out that a relative down-regulation of glycosyltransferases,
the loss of heterozygosity as well as hypermethylation of gene
promoters are possible events involved in this process.58
Some of the histo-blood group carbohydrates have high
immunogenicity and play an important role in histocompat-
ibility. A and B carbohydrates from ABO histo-blood group
system present in the vascular endothelium react with the
potent natural anti-A, anti-B, and anti-A,B antibodies acti-
vating the complement system and increasing the risk of
antibody-mediated rejection of solid organ transplantations.59
However, transplantation of solid organs from ABO incom-
patible donors has provided promising results. It has been
suggested that distinct structural differences and antigenic-
ity of the carbohydrates present in the vascular endothelium
compared to red blood cells can modulate the immune
response of the recipient thus affecting engraftment.60
However, these structural differences, as well as immune
modulator mechanisms of accommodation, have not been
clariﬁed.
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The increasing knowledge about the structural diversity of
histo-blood group carbohydrates has contributed to the devel-
opment of new technologies applied to transfusion medicine,
cancer and therapy. The insertion of function spacer lipid con-
structs allows the creation of red blood cells with a controlled
amount of carbohydrate for use in laboratory quality con-
trol of common and rare ABO and Lewis histo-blood group
phenotypes.61 This technology facilitates the evaluation of
monoclonal antibody performance in routine procedures.18
Additionally, it improves our knowledge of many  basic aspects
of hemolytic transfusions in animal models.62
Knowing the biological implications of ABO, H, secretor and
Lewis histo-blood group systems in diseases can provide the
basis for new therapeutic applications. Anti-adhesion therapy
provides an opportunity to use histo-blood group carbohy-
drates in the treatment of infections; blocking adhesion to
cells expressing these carbohydrates is an alternative strat-
egy to antibiotics. These strategies may be useful in cases of
microbial resistance to antibiotics and chemotherapy espe-
cially in patients being treated for long periods. This form of
therapy can have desirable effects at a lower cost than the pro-
duction of speciﬁc antibiotics and vaccines, including in cases
where vaccination is still not satisfactory.63,64 Additionally, the
use of carbohydrate microarrays is one of the strategies used
to explore potential natural ligands of antitumor monoclonal
antibodies which allow cancer subtyping toward identifying
targets for immunotherapy.65
Concluding  remarks
The expression of ABO, H, Lewis and secretor histo-blood
group carbohydrates is capable of producing at least three
biological effects of medical importance: structural modiﬁ-
cation of precursor oligosaccharides, expression of a distinct
carbohydrate tissue proﬁle and potent natural antibodies.15
These effects inﬂuence susceptibility to infections, since these
carbohydrates act as receptors for microorganisms or other
substances (toxins, allergens, etc.).9 Therefore these biolog-
ical events represent a vast ﬁeld for medical research and
technologies.
The tissue expression of ABH-Lewis antigens is more  com-
plex than it appears when strictly analyzed from red blood cell
phenotypes. Genes encoding FUTI, FUTII, FUTIII, GTA and GTB
are responsible for the qualitative and quantitative variabil-
ity of these antigens in mucosal and exocrine secretions.15,16
Therefore, the different polymorphic levels of ABO, H, secretor
and Lewis histo-blood group systems may have greater biolog-
ical importance than it seems from the mere  presence of their
antigens in the red blood cell membrane.2,15
There has been growing evidence that ABO, H, secretor
and Lewis histo-blood group systems are not neutral polymor-
phisms as they inﬂuence susceptibility to infections, disease
progression and innate immune response.43,52 Despite the
knowledge of some structural variability in these carbohy-
drate antigens, their polymorphic levels of expression and
potential applications in modern and personalized medicine
in the “-omics” era, little is known about their biological impor-
tance programmed in nature. New studies to understand the
relationship of these systems with microorganisms and the
environment may contribute to our understanding of the 2 0 1 6;3  8(4):331–340
evolutionary pressure that created and maintains the high
variability of polymorphisms in human beings.
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